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Molecular surveillance of multidrug-resistant tuber-
culosis (MDR-TB) using 24-loci MIRU-VNTR in the 
European Union suggests the occurrence of interna-
tional transmission. In early 2014, Austria detected 
a molecular MDR-TB cluster of five isolates. Links to 
Romania and Germany prompted the three countries 
to investigate possible cross-border MDR-TB transmis-
sion jointly. We searched genotyping databases, gen-
otyped additional isolates from Romania, used whole 
genome sequencing (WGS) to infer putative transmis-
sion links, and investigated pairwise epidemiologi-
cal links and patient mobility. Ten isolates from 10 
patients shared the same 24-loci MIRU-VNTR pattern. 
Within this cluster, WGS defined two subgroups of four 
patients each. The first comprised an MDR-TB patient 
from Romania who had sought medical care in Austria 
and two patients from Austria. The second comprised 
patients, two of them epidemiologically linked, who 
lived in three different countries but had the same city 
of provenance in Romania. Our findings strongly sug-
gested that the two cases in Austrian citizens resulted 
from a newly introduced MDR-TB strain, followed by 
domestic transmission. For the other cases, transmis-
sion probably occurred in the same city of provenance. 
To prevent further MDR-TB transmission, we need to 
ensure universal access to early and adequate therapy 
and collaborate closely in tuberculosis care beyond 
administrative borders.
Background
Tuberculosis (TB) and its multi- and extensively drug-
resistant forms (M/XDR-TB) are a major global public 
health concern. The World Health Organization (WHO) 
estimates that 9.6 million people worldwide fell ill with 
TB in 2014, of those ca 480,000 cases with MDR-TB 
[1]. Where second-line drug susceptibility testing (DST) 
is available, (pre)XDR-TB is frequently detected [2,3]. 
These patients have a high risk of death [3].
To control this infectious disease, it is key to under-
stand and interrupt the spread of TB and M/XDR-TB. 
TB transmission can be traced by classic and by 
molecular epidemiological methods. Classic methods 
include contact and source case investigations based 
on patient interviews. Molecular methods examine 
the genetic relationship between the isolates of the 
Mycobacterium tuberculosis complex. Common geno-
typing methods include spacer oligonucleotide typing 
(spoligotyping) and 24-loci mycobacterial interspersed 
repetitive units variable number of tandem repeats 
(24-loci MIRU-VNTR) analysis, both targeting specific 
small parts of the genome. Whole genome sequenc-
ing (WGS) queries the entire mycobacterial genomic 
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material. It has higher discriminatory power and may 
indicate the directionality and sequence of transmis-
sion events [4-7]. Moreover, WGS permits identification 
of genes and mutations that mediate drug resistance 
[8-11]. WGS has been employed to analyse and review 
TB outbreaks in different settings [5,12,13]. Recently, 
it has become increasingly affordable and routinely 
applicable [8,14,15].
Austria, Romania and Germany are European Union 
(EU) Member States with, respectively, TB notification 
rates of 6.8, 79.7 and 5.6 cases per 100,000 popu-
lation, rather similar proportions of MDR-TB among 
new laboratory-confirmed TB cases with DST results 
of 4.8%, 6.4% and 3.1%, yet very different absolute 
numbers of detected MDR-TB cases with 20, 517 and 87 
cases in 2014 [2].
None of the three countries has an area-wide inte-
grated molecular surveillance for TB as established 
in the Netherlands [16], the United Kingdom (UK) [17] 
or the United States (US) [18]. However, the National 
Reference Laboratories (NRLs) for Mycobacteria in 
Austria and Germany systematically type M/XDR-TB 
isolates. Germany submits the results to the geno-
typing database of the European Centre for Disease 
Prevention and Control (ECDC) [19].
In March 2014, the Austrian NRL at the Austrian Agency 
for Health and Food Safety (AGES) detected a molecu-
lar cluster of five MDR-TB cases. The question arose 
Figure 1
Cluster of multidrug-resistant tuberculosis in Austria, Romania and Germany, 2010 to 2014 (n = 13)
A. Situation as found in Austria, March 2014
D. Adding information from the epidemiological 
     investigation
E. Adding results from whole genome sequencing
B. Adding laboratory information from Germany C. Adding information from newly 
     typed isolates from Romania
Patient ID
Legend
Male patient born in Austria
Male and female patients born in Romania
Male patient born in other country
Confirmed epidemiologic link
Assumed epidemiologic link
Previous TB, year of first episode
24-loci-MIRU-VNTR cluster (numbered A, B, C)























































































ID: unique patient identifier; TB: tuberculosis; WGS: whole genome sequencing.
The panels present the findings of our cluster investigation in chronological order.
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whether MDR-TB transmission had occurred within 
Austria, which had never been observed before. Links 
to Romania and Germany prompted the three coun-
tries to investigate the MDR-TB cluster jointly within 
given legal contexts and with unchanged in-country 




The investigation team consisted of the national TB 
contact points for WHO and ECDC or representatives 
acting on their behalf, the NRLs and the responsible 
local public health authorities in Austria, Romania and 
Germany. Collaboration was maintained by monthly 
telephone conferences from April to October 2014.
Case inclusion
Cases were included without restriction in time when 
the isolate, collected in any of the three countries and 
recorded in any typing databases by the NRLs, shared 
the same spoligotype and 24-loci MIRU-VNTR pattern 
as in the initial cluster detected in Austria in March 
2014. Five MDR-TB cases from one administrative dis-
trict in Romania were included based on epidemio-
logical information in the absence of molecular typing 
data. No epidemiological links pointing to other dis-
tricts in Romania were identified.
Drug susceptibility testing
Isolates were gained by culturing specimens in liq-
uid (BACTEC MGIT 960, Becton Dickinson Diagnostic 
Systems, Sparks, US) and on solid Löwenstein-Jensen 
(LJ) media.
Figure 2
Geographical dimension of the three WGS12SNPs cluster of multidrug-resistant tuberculosis, Austria, Romania and Germany, 





Male patient born in Austria
Male and female patients born in Romania
WGS12SNPs cluster (numbered 1, 2, 3)
WGS: whole genome sequencing.
The persons are depicted in their country of residence at the beginning of the investigation, the colour refers to their country of birth (blue – 
Romania, red – Austria). The map background is used from RegioGraph (version 2015, GfK GeoMarketing GmbH, Bruchsal, Germany).
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In Austria and Germany, DST was done using the 
Mycobacteria Growth Indicator Tube (MGIT) system 
with BACTEC MGIT 960 growth supplement for DST in 
the MGIT 960 instrument (Becton Dickinson Diagnostic 
Systems, Sparks, MD). For cycloserine, the proportion 
method employed was modified according to Canetti 
[20]. In Romania, specimens were cultured on LJ 
medium. The proportion method was used to test isoni-
azid, rifampicin, ethambutol, streptomycin, kanamycin, 
amikacin, capreomycin, ofloxacin and ethionamide.
Genotyping
On extracted genomic DNA from the mycobacterial 
strains, spoligotyping and 24-loci MIRU-VNTR was 
done following standard protocols [21,22].
Whole genome sequencing and sequence data 
analysis
Libraries for sequencing were prepared from extracted 
genomic DNA with the Nextera XT library preparation 
kit and sequenced on the Illumina MiSeq next genera-
tion sequencing (NGS) platform in a 2 × 301 bp paired-
end run (Illumina, San Diego, US).
WGS data of sequenced isolates were submitted to 
the EMBL-EBI ENA sequence read archive (accession 
number: ERP013444). Resulting reads were mapped 
to the M. tuberculosis H37Rv genome (GenBank acces-
sion number: NC_000962.3) with the SARUMAN exact 
alignment tool [23]. The mean genomic coverage was 
at least 45-fold, with more than 99% of the reference 
genome covered for all isolates. Variants were called 
from mapped reads by in-house Perl scripts, asking for 
a minimum coverage of 10 reads and a minimum allele 
frequency of 75% as detection thresholds. Combining 
detected single nucleotide polymorphisms (SNPs) of 
all isolates, positions that matched the threshold lev-
els in at least 95% of all isolates were considered as 
valid and used for a concatenated sequence alignment 
excluding variants in resistance-associated or repeti-
tive regions of the genome.
We employed the BioNumerics software (Applied 
Maths NV, Belgium) to build a neighbour-joining tree 
from the 708 concatenated SNP positions. Putative 
transmission groups were predicted with a cut-off of 12 
distinct SNP positions (referred to as WGS12SNPs clus-
ters) [24].
All variants located on genes that were previously 
associated with mutations conferring drug resistance 
were extracted from the full set of detected variants, 
and the derived subset of variants was manually anno-
tated with published data [8,25-30].
Figure 3
Patient mobility per city/country and month, cluster of multidrug-resistant tuberculosis, Austria, Romania and Germany, 
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Dotted lines: assumed period of infectiousness; black diamonds: dates of notification for patients II–XIII.
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WGS was performed at the NRL at the Research Center 
Borstel in Germany.
Epidemiological investigation
We used a self-designed form in all three countries 
to systematically compile patient information, direct 
epidemiological links (exposure of at least 8 hours 
or at least 40 hours to, respectively, a sputum smear- 
or culture-positive but sputum smear-negative source 
case) [31,32], and spatio-temporal information in terms 
of the patients’ city and country of stay per month 
from January 2009 to July 2014. The data sources were 
records of the responsible authorities and re-inter-
views of the patients III, IV, V, VI. The others could not 
be contacted, had reportedly moved away or did not 
follow the invitation by the authorities.
We compiled these data into a line list using Microsoft 
Excel and analysed them descriptively.
Legal framework and data protection
Patient data had been collected as part of routine 
case notification and contact investigation accord-
ing to the Tuberculosis Law (Tuberkulosegesetz) in 
Austria, Law Number 95/2006 on Health Reform in 
Romania, and the Protection against Infection Act 
(Infektionsschutzgesetz; IfSG) in Germany.
The collection of direct person-to-person links 
required international sharing of all patients’ names. 
The Decision Number 1082/2013/EU of the European 
Parliament and of the Council [33] stipulates that 
proper authorities may communicate personal data for 
contact tracing purposes through selective exchanges 
in the European Early Warning and Response System 
(EWRS). In Germany, authorisation to collect personal 
data under the terms of section 16(1) IfSG lies with local 
public health authorities while the national authority’s 
administrative involvement in handling personal data 
(section 25(1), IfSG) is restricted to international trav-
ellers (section 12(7) International Health Regulation 
Implementation Act).
Accordingly, in Germany, one of the responsible local 
authorities compiled the patients’ names, assigned 
random unique identifiers (IDs) and redistributed the 
key to authorities in charge of the patients in the three 
countries. The form was completed using the ID, the 
key destroyed and anonymous data shared with the 
German national TB contact point at the Robert Koch 
Institute (RKI) for analysis.
The investigation protocol had been positively evalu-




In March 2014, M. tuberculosis (non-Beijing genotype) 
isolates from five MDR-TB patients in Austria were 
found to share the same spoligotype and 24-loci MIRU-
VNTR pattern ‘A’. Three patients (I–III) diagnosed from 
2010 to 2012, originated from the same city in Romania 
Table 1
Cluster of multidrug-resistant tuberculosis in Austria, Romania and Germany, demographic and clinical characteristics of 
the investigated patients, 2010 to 2014 (n = 13)
Patient ID
Country of residence 
at the beginning of the 
investigation
Sex Age group (years)
Country of 
birth
Month and year 






I Austria Female 30–39 Romania 03/2010 Yes (2001) Pulmonary
II Austria Male 50–59 Romania 01/2011 No Pulmonary
III Austria Female 30–39 Romania 03/2012 Yes (1998, 2003) Pulmonary
IV Austria Male 40–49 Austria 06/2013 No Pulmonary
V Austria Male 50–59 Austria 06/2013 No Pulmonary
VI Germany Female 30–39 Romania 12/2011 No Pulmonary
VII Germany Female 30–39 Romania 05/2011 No Pulmonary
VIII Germany Male 30–39 Nigeria 07/2011 No Extrapulmonary
IX Romania Male 40–49 Romania 01/2004 No Pulmonary
X Romania Male 50–59 Romania 12/2011 Yes (2011) Pulmonary
XI Romania Male 30–39 Romania 01/2014 No Pulmonary
XII Romania Male 20–29 Romania 12/2013 No Pulmonary
XIII Romania Female 60–69 Romania 01/2014 Yes (2004) Pulmonary





















































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































(Figure 1A, Table 1). They had moved to two different 
cities in Austria, seeking medical care for their com-
plicated MDR-TB. Two patients (IV and V) had been 
diagnosed with new MDR-TB in June 2013. They were 
residents of the same Austrian city to which patients 
I and II had moved and had no history of migration or 
international travel.
Contact tracing did not confirm any epidemiological 
link between patients I to IV. However, a link between 
patients IV and V was assumed; they had both fre-
quented the vicinity of the railway station and had 
problematic alcohol use.
Patient III reported having a sister diagnosed with 
MDR-TB living in Germany. This prompted the AGES to 
share the spoligotype and MIRU-VNTR pattern (Table 2) 
with Germany.
Germany
In early April, the NRL in Germany identified three iso-
lates with MIRU-VNTR pattern ‘A’. One isolate referred 
to the sister of patient III (patient VI), the second to 
another woman born in Romania (patient VII), and the 
third to a man born in West Africa with extrapulmonary 
non-MDR-TB (patient VIII; Figure 1B).
As five patients (I–III, VI and VII) reportedly originated 
from the same city in Romania, the Romanian national 
TB contact point was informed. In mid-April 2014, all 
three countries held their first telephone conference 
and agreed upon a joint investigation.
Romania
In Romania, in the absence of systematic MIRU-VNTR 
typing of MDR-TB strains, isolates from all five MDR-TB 
patients (IX–XIII) ever reported in the corresponding 
district were typed at the Austrian NRL. The isolate 
from patient IX had a unique MIRU-VNTR pattern ‘B’, 
the isolates from patients X and XI shared pattern ‘A’, 
and the ones from patients XII and XIII shared a dis-
tinct pattern ‘C’ and a different spoligotype (Figure 1C, 
Table 2).
Epidemiological investigation
Investigation forms were completed for patients II–XIII 
by seven public health authorities by September 2014. 
For patient I, only a laboratory report was available.
All patients were adults, five women and eight men; six 
had experienced migration (I–III and VI–VIII). Nine had 
new TB, four (I, III, X and XIII) had had previous TB, the 
first TB diagnosis dating back to year 1998 (III). All but 
patient VIII had pulmonary TB (Table 1).
The two sisters (III and VI) were confirmed to have a 
direct epidemiological link between them. Direct links 
were ruled out for persons II, III, IV, V, VII, IX and XII, 
and unknown for VI, VIII, X, XI and XIII. The assumed 
link between cases IV and V was negated when re-
interviewing the persons (Figure 1D).
The two sisters (III and VI) had crossed borders pre-
sumably while being infectious (Figures 2 and 3). Other 
patients with migration background had moved before 
2009 (II) or at an unknown date (I, VII, VIII). The mobil-
ity pattern did not preclude TB transmission events 
from patient II to patients IV and V in Austria, nor from 
patient III to patients X–XIII in Romania. The sisters 
III and VI had a space–time correlation in Romania in 
August 2011, however, only about one month before 
the beginning of the assumed infectious period of 
patient VI.
Table 3
Phenotypic drug susceptibility testing results, cluster investigation of multidrug-resistant tuberculosis, Austria, Romania 
and Germany, 2010 to 2014 (n = 13)
ID H R Z E Eth Pt PAS Rb Cs S Amk Kan Cap Ofl Mox Lev
I Res Res Res Sus ND Res Sus Res Sus Sus Sus ND Sus Res Res ND
II Res Res Res Res ND Res Sus Res Sus Res Sus ND Sus Sus ND ND
III Res Res Res Res Res Res Sus Res Res Res Sus ND Sus Res Res Res
IV Res Res Res Sus ND Res Sus Res Sus Res Sus ND Sus Sus Sus ND
V Res Res Res Sus Res Res Sus Res Sus Res Sus ND Sus Sus Sus ND
VI Res Res Res Res Res Res Sus Res Sus Res Res ND Res Sus ND ND
VII Res Res Res Res Res Res Sus Res Sus Res Sus ND Sus Sus ND ND
VIII Res Sus Res Sus Res Res ND ND ND Res ND ND Sus Sus ND ND
IX Res Res ND ND ND ND ND ND ND Res ND ND ND ND ND ND
X Res Res ND Res Sus ND ND ND ND Res Res Res Res Sus ND ND
XI Res Res ND Res Sus ND ND ND ND Res Sus Sus Sus Sus ND ND
XII Res Res ND Sus Sus ND ND ND ND Res Sus Sus Sus Sus ND ND
XIII Res Res ND Sus Sus ND ND ND ND Res Sus Sus Sus Sus ND ND
Amk: amikacin; Cap: capreomycin; E: ethambutol; Eth: ethionamide; ID: unique patient identifier; Kan: kanamycin; Lev: levofloxacin; Mox: 
moxifloxacin; ND: no data; H: isoniazid; Ofl: ofloxacin; PAS: para-aminosalicylic acid; Pt: protionamide; R: rifampicin; Rb: rifabutin; Res: 
resistant; Cs: cycloserine; S: streptomycin; Sus: susceptible; Z: pyrazinamide.
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Whole genome sequencing
WGS was completed by August 2014. WGS12SNPs 
divided cluster ‘A’ into two subgroups (one compris-
ing patients II, IV, V and X, the other patients III, VI, 
VII and XI), and two separate cases (I and VIII). The 
third WGS12SNPs cluster was congruent with genotyp-
ing pattern ‘C’ (Figure 1E). The isolates from patients 
II and IV, as well as II and V were distinct by 3 and 4 
SNPs, respectively. Isolates from patients XII and XIII 
were genetically identical (0 SNPs). The isolates from 
the epidemiologically linked sisters were distinct by 12 
SNPs.
The first two WGS12SNPs clusters spanned across bor-
ders, while the third was domestic (Figure 2).
The detected mutations mediating resistance to first-
line drugs correlated with phenotypic DST results. 
The isoniazid resistance-conferring mutation S315T in 
katG fully matched phenotypic isoniazid resistance; 
the same was observed for S450L or T400A in rpoB 
and rifampicin/rifabutin resistance and A146V in pncA 
and pyrazinamid resistance (information missing for 
patients IX–XIII). Two phenotypical ethambutol-suscep-
tible isolates harboured the known resistance-medi-
ating mutation M306I in embB; the resistant isolates 
showed either the mutation M306I or a combination of 
two mutations G406S and D1024N.
In addition, we detected resistance-mediating muta-
tions for streptomycin (rpsL K43R) and kanamycin/
amikacin (rrs 1401 A -> G). One of two quinolone-resist-
ant isolates shows a mutation in gyrA (A288D), a qui-
nolone resistance-associated gene. Among the five 
isolates phenotypically resistant to ethionamide, one 
harboured a frameshift insertion in ethA. Four out of 
eight phenotypical protionamide-resistant isolates, 
showed frameshift insertions in ethA (Tables 3 and 4). 
Patients in one WGS cluster shared a cluster-specific 
set of resistance-mediating mutations, patient X in 
cluster 1 and patient VI in cluster 2 had acquired an 
additional aminoglycoside resistance (rrs 1401 A -> G).
Discussion
We investigated a molecular cluster of MDR-TB in 
Austria, Romania and Germany. WGS combined with 
epidemiological information showed that isolates from 
patient II, seeking medical care in Austria, differed from 
the subsequently diagnosed Austrian patients IV and 
V by only 3 and 4 SNPs, respectively. This suggested 
that two MDR-TB transmission events had occurred in 
Austria. Isolates from patients III, VI, VII and XI, who 
Table 4
Genotypic drug susceptibility testing results, cluster of multidrug-resistant tuberculosis, Austria, Romania and Germany, 
2010 to 2014 (n = 13)
ID
H R R Z E E E Eth/Pt Eth/Pt Ami S SM PAS FQ
Rv1908c Rv0667 Rv0667 Rv2043c Rv3795 Rv3795 Rv3795 Rv3854c Rv3854c MTB000019 Rv3919c Rv0682 Rv2764c Rv0007








[8,28] ethA [29] ethA [29] Rrs [8] gidB [25] rpsL [25] thyA [30] gyrA [8]
I S315T a WT S450L a A146V a WT WT D1024N b WT
Ins 802 
ag b WT Q125_ 
b WT R222Cb A288Db
II S315T a WT S450L a A146V a M306I a WT WT Ins 1391 a b WT WT Q125_ 
b WT WT WT
III S315T a WT S450L a A146V a WT G406Sa D1024N b WT WT WT Q125_ b WT WT WT
IV S315T a WT S450L a A146V a M306I a WT WT Ins 1391 a b WT WT Q125_ 
b WT WT WT
V S315T a WT S450L a A146V a M306I a WT WT Ins 1391 a b WT WT Q125_ 
b WT WT WT
VI S315T a WT S450L a A146V a WT G406S a D1024N b WT WT 1401 A -> G a Q125_ b WT WT WT
VII S315T a WT S450L a A146V a WT G406S a D1024N b WT WT WT Q125_ b WT WT WT
VIII S315T a WT WT A146V a WT WT WT WT WT WT Q125_ b WT WT WT
IX S315T a WT S450L a A146V a M306I a WT D1024N b WT WT WT Q125_ b WT WT WT
X S315T a WT S450L a A146V a M306I a WT WT Ins 1391 a b WT 1401 A- > G 
a Q125_ b WT WT WT
XI S315T a WT S450L a A146V a WT G406S a D1024N b WT WT WT Q125_ b WT WT WT
XII S315T a T400A a S450L a WT WT WT WT WT WT WT WT K43R1 WT WT
XIII S315T a T400A a S450L a WT WT WT WT WT WT WT WT K43R1 WT WT
Ami: aminoglycoside; E: ethambutol; Eth: ethionamide; FQ: fluroquinolones; ID: unique patient identifier; H: isoniazid; PAS: para-
aminosalicylic acid; Pt: protionamide; R: rifampicin; S: streptomycin; Z: pyrazinamide; WT: wild type.
a resistance mediating mutation.
b resistance associated variant.
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lived in three different countries but had the same city 
of provenance, differed by 6–12 SNPs from each other. 
Here, transmission is likely to have occurred before the 
patients moved abroad.
Close genetic similarity of isolates from different 
patients is highly unlikely to occur by chance. From 
well-described TB outbreaks we know that isolates 
gained within three years from patients with a direct 
epidemiological link usually differ by 5 or fewer SNPs 
[34,35]. In an outbreak of nine drug-susceptible TB 
cases in San Francisco, US, the isolates differed by 
0–2 SNPs per any transmission event that had resulted 
in a secondary case [6]. In a similar investigation in 
Germany, differences of 0–3 SNPs were found (n = 31) 
[7]. From a retrospective study of TB outbreaks, Walker 
and colleagues derived that epidemiological linkage 
is expected to be consistent with sequenced isolates 
differing in up to 5 SNPs; the absence of an epidemio-
logical link is consistent with more than 12 SNPs, while 
pairs of 6–12 SNPs were considered to be indetermi-
nate [24].
In our investigation, isolates from the two epidemiolog-
ically linked sisters differed by 12 SNPs. This strongly 
suggests one or more missing links in the transmission 
chain, namely a common source case for both sisters 
with possibly additional intermediate cases. Missing 
links may be the result of undetected TB cases, the 
restriction of our investigation to only one district 
in Romania, unavailable genotyping results, or from 
selection based on identical MIRU-VNTR patterns when 
a mutation affected a VNTR locus even though isolates 
differed only by few SNPs [6].
We investigated a single scenario and may not draw 
conclusions about the extent of cross-border transmis-
sion of MDR-TB in the EU. The ECDC MDR-TB molecu-
lar surveillance project investigated 2,092 MIRU-VNTR 
patterns of isolates from 24 contributing EU Member 
States from 2003 to 2011 [19]. In total, 941 cases in 79 
European multiple-country clusters were detected and 
1,086 cases were allocated to national clusters. That 
study was solely based on genotyping data. In the UK, 
24-loci MIRU-VNTR typing and epidemiological surveil-
lance data were linked and jointly interpreted, and 
8.5% of the MDR-TB cases were attributed to recent 
domestic transmission [36]. Similar nationwide evalu-
ations are missing for our countries.
A high proportion of imported MDR-TB in low-incidence 
countries does not necessarily entail ongoing MDR-TB 
transmission when early case detection, infection con-
trol and adequate treatment succeed [19]. A systematic 
review for the EU/European Economic Area indicates 
that TB in the foreign-born population has no signifi-
cant influence on TB in the native population [37].
Beyond higher resolution in TB outbreak investigation, 
WGS provided us in addition with information on drug 
resistance of the bacteria. We could identify mutations 
mediating pyrazinamide resistance in previously not 
tested isolates and mutations mediating ethambutol 
resistance in two samples with susceptible phenotypic 
DST results. However, our data on mutations mediating 
drug resistance to ethionamide, protionamide and the 
quinolones showed discrepancies between phenotypi-
cal and genotypical DST. A comprehensive database of 
characterised mutations is needed to extend the usa-
bility of WGS in predicting drug resistance, e.g. in order 
to provide rapid and effective treatment in outbreaks 
of drug-resistant TB. The concordance of resistance-
mediating mutations in each WGS cluster confirmed 
transmission of MDR strains rather than treatment fail-
ure and new acquisition of MDR in each patient [10].
Our investigation was subject to limitations. The col-
lection of direct epidemiological links yielded little 
information. It was difficult to differentiate whether a 
specific contact was absent (e.g. due to missing links), 
unknown (exposures in public space, recall bias) or 
non-reported (reluctance to name persons). Spatio-
temporal data did not cover all patients’ presumed 
infectious periods and travel history. Their low resolu-
tion (per city/country and month) allowed us to judge 
whether a contact was possible at all, but not to explore 
new exposure settings or events. More detailed inves-
tigations are difficult given long infectious periods and 
serial intervals in TB transmission chains.
The clinical characteristics ‘cavitary disease’ and ‘HIV 
status’ were not assessed as they are not notifiable 
everywhere, although relevant to assessing infectious-
ness and transmission risks. For patient I, it remained 
unclear which local public health authority was in 
charge. This highlights the challenge in transferring 
patient reports when patients are highly mobile.
We learned that the choice of methods and the order in 
which we use them can play a significant role. If WGS 
had been used initially and had led to the detection of 
the close genetic relationship between isolates from 
patients II, IV and V in Austria, a cross-border investi-
gation might not have been initiated.
The cross-border investigation of a single genotyping 
cluster of TB can become complex and labour-intensive 
with uncertain public health benefits. In our case, there 
were no implications for contact tracing, which had 
already been completed. However, such investigation 
as ours may detect previously undetected individuals 
with TB. While investigations might get more efficient 
with increasing routine, each cluster brings together a 
new group of competent authorities that need to estab-
lish collaboration. Systematic and timely integration of 
genotyping and sequencing data into TB surveillance 
improves the understanding of transmission in a given 
country and internationally [38].
Topical issues remain: Should WGS replace 24-loci 
MIRU-VNTR as a standard? By when? How should we 
collect, analyse and interpret sequencing data within 
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routine TB surveillance [39] and evaluate utility? How 
should we prioritise cluster investigations? Are there 
reliable predictors of cluster growth [40-43]? Will epi-
demiological links remain an essential component in 
TB outbreak definitions, i.e. may we use the term ‘out-
break’ solely based on WGS results when epidemiolog-
ical links cannot confirmed? How can we collaborate 
most efficiently across borders when contact networks 
are complex and personal data are to be shared by eve-
ryone with everyone else? Could a secure interactive 
online platform complement communication channels 
such as EWRS?
Conclusion
Our joint cross-border investigation clarified a trans-
boundary MDR-TB transmission scenario. The applied 
methods complemented each other: genotyping results 
prompted our investigation, classic epidemiological 
data anchored the cluster in time and space, and WGS 
allowed a high resolution of transmission and new 
information on drug-resistance.
To prevent further MDR-TB transmission within and 
between countries, we need to ensure universal access 
to early and adequate therapy in order to reduce incen-
tives to seek medical care abroad and to ensure infec-
tion control and seamless collaboration in TB care 
beyond administrative borders [44].
Acknowledgements
We would like to thank the following persons from the re-
sponsible authorities and TB patient services in Romania, 
Austria and Germany for their support of our investigation: Dr 
Georgeta Marga, Dr Lavinia Danciu, Dr Ioan Campean, Ursula 
Tuch, Dr Ulrike Meixner-Gruber, Dr Marianne Wassermann-
Neuhold, Dr Johannes Donhauser, Andrea Hingerl, Ludger 
Staufenbiel, Dr Wolfgang Hautmann, Dr Johannes Dreesman, 
and Dr Dr Günther Pfaff. We further thank Dr Alyssa Finlay 
and the CDC Division of TB Elimination for helpful comments 
on the analysis.
We acknowledge the European Union PathoNgenTrace (FP7-
278864-2) project and the German Center for Infection 
Research (DZIF) for their financial support for WGS.
Declaration of interests
The authors declare that they have no competing interests.
Role of the funding source: The WGS has been financially 
supported by the European Union PathoNgenTrace (FP7–
278864–2) project and the German Center for Infection 
Research (DZIF). For other parts of the investigation there 
was no external funding source. The funders had no role in 
study design, data collection and analysis, decision to pub-
lish, or preparation of the manuscript.
Authors’ contributions
Designed and led the investigation via phone conferences: 
LF, FA, OP, SN, ER, SRG, AI, MM, BS, DC, DH, BH, WH; col-
lected epidemiological data: MM, OP, BS, AI, LF; analysed 
epidemiological data: LF; interpreted epidemiological find-
ings: LF, WH, BH, FA, OP; performed laboratory analyses 
and genotyping: AI, DH, ER, SRG, SN; performed WGS and 
sequence data analysis: TK, PB, SN; wrote the manuscript: 
LF; helped to draft the manuscript: TK, PB. All authors criti-
cally revised the manuscript and approved the final version.
References
1. World Health Organization (WHO). Global tuberculosis 
report 2015. Geneva: WHO; 2015. WHO/HTM/
TB/2015.22. Available from: http://apps.who.int/iris/
bitstream/10665/191102/1/9789241565059_eng.pdf
2. European Centre for Disease Prevention and Control 
(ECDC)/WHO Regional Office for Europe. Tuberculosis 
surveillance and monitoring in Europe 2016. Stockholm: 
ECDC; 2016. Available from: http://ecdc.europa.eu/en/
publications/_layouts/forms/Publication_DispForm.
aspx?List=4f55ad51-4aed-4d32-b960-af70113dbb90&ID=1452
3. Balabanova Y, Ignatyeva O, Fiebig L, Riekstina V, Danilovits M, 
Jaama K,  et al.  Survival of patients with multidrug-resistant 
tuberculosis in Eastern Europe: what makes a difference? 
Thorax. 2016;71(9):854-61.
4. Niemann S, Köser CU, Gagneux S, Plinke C, Homolka S, 
Bignell H,  et al.  Genomic diversity among drug sensitive and 
multidrug resistant isolates of Mycobacterium tuberculosis 
with identical DNA fingerprints. PLoS One. 2009;4(10):e7407. 
DOI: 10.1371/journal.pone.0007407
5. Roetzer A, Diel R, Kohl TA, Rückert C, Nübel U, Blom J,  et 
al.  Whole genome sequencing versus traditional genotyping 
for investigation of a Mycobacterium tuberculosis outbreak: 
a longitudinal molecular epidemiological study. PLoS Med. 
2013;10(2):e1001387. DOI: 10.1371/journal.pmed.1001387
6. Kato-Maeda M, Ho C, Passarelli B, Banaei N, Grinsdale J, 
Flores L,  et al.  Use of whole genome sequencing to determine 
the microevolution of Mycobacterium tuberculosis during an 
outbreak. PLoS One. 2013;8(3):e58235. DOI: 10.1371/journal.
pone.0058235
7. Schürch AC, Kremer K, Daviena O, Kiers A, Boeree MJ, 
Siezen RJ,  et al.  High-resolution typing by integration of 
genome sequencing data in a large tuberculosis cluster. J Clin 
Microbiol. 2010;48(9):3403-6. DOI: 10.1128/JCM.00370-10
8. Campbell PJ, Morlock GP, Sikes RD, Dalton TL, Metchock B, 
Starks AM,  et al.  Molecular detection of mutations associated 
with first- and second-line drug resistance compared with 
conventional drug susceptibility testing of Mycobacterium 
tuberculosis. Antimicrob Agents Chemother. 2011;55(5):2032-
41. DOI: 10.1128/AAC.01550-10
9. Comas I, Borrell S, Roetzer A, Rose G, Malla B, Kato-
Maeda M,  et al.  Whole-genome sequencing of rifampicin-
resistant Mycobacterium tuberculosis strains identifies 
compensatory mutations in RNA polymerase genes. Nat Genet. 
2011;44(1):106-10. DOI: 10.1038/ng.1038
10. Walker TM, Kohl TA, Omar SV, Hedge J, Del Ojo Elias C, 
Bradley P,  et al. , Modernizing Medical Microbiology (MMM) 
Informatics Group. Whole-genome sequencing for prediction 
of Mycobacterium tuberculosis drug susceptibility and 
resistance: a retrospective cohort study.Lancet Infect Dis. 
2015;15(10):1193-202. DOI: 10.1016/S1473-3099(15)00062-6
11. Outhred AC, Jelfs P, Suliman B, Hill-Cawthorne GA, Crawford 
AB, Marais BJ,  et al.  Added value of whole-genome 
sequencing for management of highly drug-resistant TB. J 
Antimicrob Chemother. 2015;70(4):1198-202.
12. Gardy JL, Johnston JC, Ho Sui SJ, Cook VJ, Shah L, Brodkin E,  et 
al.  Whole-genome sequencing and social-network analysis of 
a tuberculosis outbreak. N Engl J Med. 2011;364(8):730-9. DOI: 
10.1056/NEJMoa1003176
13. Stucki D, Ballif M, Bodmer T, Coscolla M, Maurer AM, Droz S,  
et al.  Tracking a tuberculosis outbreak over 21 years: strain-
specific single-nucleotide polymorphism typing combined 
with targeted whole-genome sequencing. J Infect Dis. 
2015;211(8):1306-16.
14. Köser CU, Ellington MJ, Cartwright EJP, Gillespie SH, Brown NM, 
Farrington M,  et al.  Routine use of microbial whole genome 
sequencing in diagnostic and public health microbiology. 
PLoS Pathog. 2012;8(8):e1002824. DOI: 10.1371/journal.
ppat.1002824
15. Walker TM, Monk P, Smith EG, Peto TE. Contact investigations 
for outbreaks of Mycobacterium tuberculosis: advances 
through whole genome sequencing.Clin Microbiol Infect. 
2013;19(9):796-802. DOI: 10.1111/1469-0691.12183
16. Lambregts-van Weezenbeek CS, Sebek MM, van Gerven 
PJ, de Vries G, Verver S, Kalisvaart NA,  et al.  Tuberculosis 
11www.eurosurveillance.org
contact investigation and DNA fingerprint surveillance in The 
Netherlands: 6 years’ experience with nation-wide cluster 
feedback and cluster monitoring. Int J Tuberc Lung Dis. 
2003;7(12) Suppl 3;S463-70.
17. Mears J, Abubakar I, Crisp D, Maguire H, Innes JA, Lilley 
M,  et al.  Prospective evaluation of a complex public health 
intervention: lessons from an initial and follow-up cross-
sectional survey of the tuberculosis strain typing service 
in England. BMC Public Health. 2014;14(1):1023. DOI: 
10.1186/1471-2458-14-1023
18. Centers for Disease Prevention and Control (CDC). TB 
genotyping information management system (TB GIMS). 
Atlanta: CDC. [Accessed: 31 March 2016]. Available from: 
http://www.cdc.gov/tb/programs/genotyping/tbgims/default.
htm
19. De Beer JL, Kodmon C, van der Werf MJ, van Ingen J, van 
Soolingen D. ECDC MDR-TB molecular surveillance project 
participants. Molecular surveillance of multi- and extensively 
drug-resistant tuberculosis transmission in the European 
Union from 2003 to 2011.Euro Surveill. 2014;19(11):20742. DOI: 
10.2807/1560-7917.ES2014.19.11.20742
20. Canetti G, Fox W, Khomenko A, Mahler HT, Menon NK, 
Mitchison DA,  et al.  Advances in techniques of testing 
mycobacterial drug sensitivity, and the use of sensitivity tests 
in tuberculosis control programmes. Bull World Health Organ. 
1969;41(1):21-43.
21. van Embden JD, Cave MD, Crawford JT, Dale JW, Eisenach 
KD, Gicquel B,  et al.  Strain identification of Mycobacterium 
tuberculosis by DNA fingerprinting: recommendations for a 
standardized methodology. J Clin Microbiol. 1993;31(2):406-9.
22. Kamerbeek J, Schouls L, Kolk A, van Agterveld M, van 
Soolingen D, Kuijper S,  et al.  Simultaneous detection 
and strain differentiation of Mycobacterium tuberculosis 
for diagnosis and epidemiology. J Clin Microbiol. 
1997;35(4):907-14.
23. Blom J, Jakobi T, Doppmeier D, Jaenicke S, Kalinowski J, Stoye 
J,  et al.  Exact and complete short-read alignment to microbial 
genomes using Graphics Processing Unit programming. 
Bioinformatics. 2011;27(10):1351-8. DOI: 10.1093/
bioinformatics/btr151
24. Walker TM, Ip CL, Harrell RH, Evans JT, Kapatai G, Dedicoat MJ,  
et al.  Whole-genome sequencing to delineate Mycobacterium 
tuberculosis outbreaks: a retrospective observational 
study. Lancet Infect Dis. 2013;13(2):137-46. DOI: 10.1016/
S1473-3099(12)70277-3
25. Feuerriegel S, Oberhauser B, George AG, Dafae F, Richter E, 
Rüsch-Gerdes S,  et al.  Sequence analysis for detection of 
first-line drug resistance in Mycobacterium tuberculosis strains 
from a high-incidence setting. BMC Microbiol. 2012;12(1):90. 
DOI: 10.1186/1471-2180-12-90
26. Marttila HJ, Soini H, Huovinen P, Viljanen MK. katG mutations 
in isoniazid-resistant Mycobacterium tuberculosis isolates 
recovered from Finnish patients.Antimicrob Agents Chemother. 
1996;40(9):2187-9.
27. Miotto P, Cabibbe AM, Feuerriegel S, Casali N, Drobniewski F, 
Rodionova Y,  et al.  Mycobacterium tuberculosis pyrazinamide 
resistance determinants: a multicenter study. MBio. 
2014;5(5):e01819-14. DOI: 10.1128/mBio.01819-14
28. Plinke C, Cox HS, Zarkua N, Karimovich HA, Braker K, Diel R,  et 
al.  embCAB sequence variation among ethambutol-resistant 
Mycobacterium tuberculosis isolates without embB306 
mutation. J Antimicrob Chemother. 2010;65(7):1359-67. DOI: 
10.1093/jac/dkq120
29. DeBarber AE, Mdluli K, Bosman M, Bekker LG, Barry CE. 
Ethionamide activation and sensitivity in multidrug-resistant 
Mycobacterium tuberculosis.Proc Natl Acad Sci USA. 
2000;97(17):9677-82. DOI: 10.1073/pnas.97.17.9677
30. Rengarajan J, Sassetti CM, Naroditskaya V, Sloutsky A, 
Bloom BR, Rubin EJ. The folate pathway is a target for 
resistance to the drug para-aminosalicylic acid (PAS) in 
mycobacteria.Mol Microbiol. 2004;53(1):275-82. DOI: 
10.1111/j.1365-2958.2004.04120.x
31. Diel R, Loytved G, Nienhaus A, Castell S, Detjen A, 
Geerdes-Fenge H, et al. Neue Empfehlungen für die 
Umgebungsuntersuchungen bei Tuberkulose. [New 
recommendations for contact tracing in tuberculosis]. 
Gesundheitswesen. 2011;73(6):369-88. German. http://dx.doi.
org/DOI: 10.1055/s-0030-1256574 PMID:21695661
32. Bogyi M, Hagel E, Hirtl T, Klein JP, Rumetshofer R, Wolf 
K, et al. Österreichische Leitlinie zur Tuberkulose – 
Umgebungsuntersuchung. [Austrian guidelines for 
tuberculosis contact tracing]. Vienna: Bundesministerium 
für Gesundheit (BMG). [Accessed: 31 March 2016]. 
German. Available from: http://www.bmgf.gv.at/home/
Leitlinie_Tuberkulose_Umgebungsuntersuchung
33. Decision No. 1082/2013/EU of the European Parliament 
and the council of the European Union of 22 October 
2013 on serious cross-border threats to health and 
repealing Decision No 2119/98/EC. Offical Journal of the 
European Union. Luxembourg: Publications Office of the 
European Union. 5.11.2013:L 293. Available from: http://
ec.europa.eu/health/preparedness_response/docs/
decision_serious_crossborder_threats_22102013_en.pdf
34. Perez-Lago L, Comas I, Navarro Y, Gonzalez-Candelas F, 
Herranz M, Bouza E et al. Whole genome sequencing analysis 
of intrapatient microevolution in Mycobacterium tuberculosis: 
potential impact on the inference of tuberculosis transmission. 
J Infect Dis. 2014;209:98e108.
35. Schürch AC, Kremer K, Kiers A, Daviena O, Boeree MJ, Siezen 
RJ,  et al.  The tempo and mode of molecular evolution of 
Mycobacterium tuberculosis at patient-to-patient scale. 
Infect Genet Evol. 2010;10(1):108-14. DOI: 10.1016/j.
meegid.2009.10.002
36. Anderson LF, Tamne S, Brown T, Watson JP, Mullarkey C, Zenner 
D,  et al.  Transmission of multidrug-resistant tuberculosis 
in the UK: a cross-sectional molecular and epidemiological 
study of clustering and contact tracing. Lancet Infect Dis. 
2014;14(5):406-15. DOI: 10.1016/S1473-3099(14)70022-2
37. Sandgren A, Schepisi MS, Sotgiu G, Huitric E, Migliori GB, 
Manissero D,  et al.  Tuberculosis transmission between 
foreign- and native-born populations in the EU/EEA: a 
systematic review. Eur Respir J. 2014;43(4):1159-71. DOI: 
10.1183/09031936.00117213
38. Coscolla M, Barry PM, Oeltmann JE, Koshinsky H, Shaw T, 
Cilnis M,  et al.  Genomic epidemiology of multidrug-resistant 
Mycobacterium tuberculosis during transcontinental spread. J 
Infect Dis. 2015;212(2):302-10. DOI: 10.1093/infdis/jiv025
39. Kohl TA, Diel R, Harmsen D, Rothgänger J, Walter KM, Merker 
M,  et al.  Whole-genome-based Mycobacterium tuberculosis 
surveillance: a standardized, portable, and expandable 
approach. J Clin Microbiol. 2014;52(7):2479-86. DOI: 10.1128/
JCM.00567-14
40. Driver CR, Macaraig M, McElroy PD, Clark C, Munsiff SS, 
Kreiswirth B,  et al.  Which patients’ factors predict the rate 
of growth of Mycobacterium tuberculosis clusters in an urban 
community? Am J Epidemiol. 2006;164(1):21-31. DOI: 10.1093/
aje/kwj153
41. Kik SV, Verver S, van Soolingen D, de Haas PE, Cobelens 
FG, Kremer K,  et al.  Tuberculosis outbreaks predicted by 
characteristics of first patients in a DNA fingerprint cluster. 
Am J Respir Crit Care Med. 2008;178(1):96-104. DOI: 10.1164/
rccm.200708-1256OC
42. Althomsons SP, Kammerer JS, Shang N, Navin TR. Using 
routinely reported tuberculosis genotyping and surveillance 
data to predict tuberculosis outbreaks.PLoS One. 
2012;7(11):e48754. DOI: 10.1371/journal.pone.0048754
43. Oeltmann JE, Click ES, Moonan PK. Using tuberculosis patient 
characteristics to predict future cases with matching genotype 
results.Public Health Action. 2014;4(1):47-52. DOI: 10.5588/
pha.13.0098
44. Dara M, de Colombani P, Petrova-Benedict R, Centis R, 
Zellweger JP, Sandgren A,  et al.  Minimum package for cross-
border TB control and care in the WHO European region: a 
Wolfheze consensus statement. Eur Respir J. 2012;40(5):1081-
90. DOI: 10.1183/09031936.00053012
License and copyright
This is an open-access article distributed under the terms of 
the Creative Commons Attribution (CC BY 4.0) Licence. You 
may share and adapt the material, but must give appropriate 
credit to the source, provide a link to the licence, and indi-
cate if changes were made.
This article is copyright of the authors, 2017.
